Lower response to BNT162b2 vaccine in patients with myelofibrosis compared to polycythemia vera and essential thrombocythemia
In: Journal of Hematology & Oncology, Jg. 14 (2021), Heft 1, S. 1-4
Online
unknown
Zugriff:
In a population of 42 Philadelphia negative myeloproliferative neoplasm patients, all on systemic active treatment, the likelihood of responding to anti-SARS-CoV-2 BNT162b2 vaccine at 2 weeks after the second dose was significantly lower in the ten patients with myelofibrosis compared to the 32 with essential thrombocythemia (n = 17) and polycythemia vera (n = 15) grouped together, both in terms of neutralizing anti-SARS-CoV-2 IgG titers and seroprotection rates (32.47 AU/mL vs 217.97 AU/mL, p = 0.003 and 60% vs 93.8%, p = 0.021, respectively). Ruxolitinib, which was the ongoing treatment in five patients with myelofibrosis and three with polycythemia vera, may be implicated in reducing vaccine immunogenicity (p = 0.076), though large prospective study is needed to address this issue.
Titel: |
Lower response to BNT162b2 vaccine in patients with myelofibrosis compared to polycythemia vera and essential thrombocythemia
|
---|---|
Autor/in / Beteiligte Person: | Antonia La Malfa ; Pimpinelli, Fulvia ; Pontone, Martina ; Mengarelli, Andrea ; Spadea, Antonio ; Laquintana, Valentina ; Ensoli, Fabrizio ; Marchesi, Francesco ; Vujovic, Branka ; Morrone, Aldo ; Piaggio, Giulia ; Ciliberto, Gennaro ; Giannarelli, Diana ; Simona di Martino ; Falzone, Gianluca ; Enea Gino Di Domenico ; Ornella Di Bella ; Falcucci, Paolo ; Papa, Elena |
Link: | |
Zeitschrift: | Journal of Hematology & Oncology, Jg. 14 (2021), Heft 1, S. 1-4 |
Veröffentlichung: | BioMed Central, 2021 |
Medientyp: | unknown |
Schlagwort: |
|
Sonstiges: |
|